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Institute of Biostatistics, China Medical University, Taichung, TaiwanA B S T R A C TBackground: Different end-point measures may contribute to incon-
sistent therapeutic responses in relief of laryngopharyngeal reﬂux (LPR)
symptoms. Objectives: We aimed to determine an a priori responder
deﬁnition for a patient-reported outcome instrument, the Reﬂux Symp-
tom Index (RSI), using an anchor-based method, to interpret individual
treatment beneﬁt in patients with LPR, on the basis of the US Food and
Drug Administration guidance. Methods: Patients with chronic laryng-
eal symptoms suggestive of LPR underwent twice-daily 40 mg esome-
prazole treatment for 12 weeks. We used a 50% or more reduction in the
primary laryngeal symptom at week 12, an empirical criterion, as an
anchor to dichotomize the participants into two groups, and to establish
a responder deﬁnition of the RSI score change. The optimal cutoff point
of the RSI score change was determined on the basis of the maximal
Youden index of the receiver operating characteristic analysis. Results:
The mean reduction in the RSI score was signiﬁcantly greater inee front matter Copyright & 2015, International S
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0402.subjects with a 50% or more reduction in the primary laryngeal
symptom than in those without (11.0  7.8 vs. 3.1  8.3, P o
0.0001). A reduction of six points or more in the RSI score at week 12 was
considered to be the responder deﬁnition with a sensitivity of 0.79 and a
speciﬁcity of 0.70. Conclusions: We propose an a priori responder
deﬁnition derived from an empirical criterion according to the Food
and Drug Administration guidance: a reduction of six points or more in
the RSI score at week 12. This preliminary estimate provides a clinically
meaningful change at an individual level, although additional studies
and validations across various languages are required.
Keywords: anchor-based method, laryngopharyngeal reﬂux, patient-
reported outcome, responder deﬁnition.
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Laryngopharyngeal reﬂux (LPR) or reﬂux laryngitis is an established
extraesophageal manifestation of gastroesophageal reﬂux disease
[1,2]. Management of LPR, however, is controversial because although
treatment with proton pump inhibitors (PPIs) is often recommended
[3,4], the treatment efﬁcacy remains inconsistent among controlled
trials [5–7]. Inappropriate instruments and/or inconsistent end-point
measures of patient-reported outcomes (PROs) may explain, at least
in part, the failure to demonstrate any treatment beneﬁt [7]. For
example, none of the eight randomized placebo-controlled trials in a
meta-analysis used validated disease-speciﬁc PRO instruments for
demonstrating treatment beneﬁt of PPIs [5].The Reﬂux Symptom Index (RSI) is a disease-speciﬁc self-
administered questionnaire used for evaluation of LPR symptom
severity. It was developed and psychometrically validated in a
sample of patients with LPR [8], has been used in centers worldwide
for many years, and has been translated into several languages [9–
12]. In addition, two recent randomized controlled trials used the
RSI and found that PPIs were more effective than the placebo [6,7].
Although a disease-speciﬁc instrument can be used to measure
PRO, a statistically signiﬁcant score change may not be clinically
relevant [13]. Subsequently, minimally important differences, deﬁned
as the smallest meaningful difference derived from point esti-
mates of mean differences among groups, may mask important
changes for individuals [14]. Recently, the US Food and Drugociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 9 6 – 4 0 3 397Administration (FDA) released a PRO guidance [15] that recom-
mended determining an a priori responder deﬁnition for PRO
instruments, that is, the change in an individual patient’s PRO
score over a predetermined time period that can be considered to
constitute a treatment beneﬁt. In the guidance, anchor-based
methods using an empirical criterion such as patient rating of
change on exit from a clinical trial are recommended to establish a
responder deﬁnition, whereas distribution-based methods are
considered to play a supportive role [15]. Moreover, a proportion
of treatment responders can be calculated to compare group
differences in addition to assessing the conventional mean differ-
ences between groups. Therefore, this approach is advantageous
in both clinical practice and clinical trials for the interpretation of
individual and group treatment beneﬁts, respectively.
Previously, de Vet et al. [16] proposed an anchor-based
minimally important change distribution method to assess min-
imally important changes. They dichotomized the patients into
“important improvement” and “no important change” according
to a predeﬁned anchor, and then determined a cutoff value on
the score change of the PRO instrument on the basis of the
maximal Youden index of the receiver operative characteristic
(ROC) curve or the 95% limit. Their method takes advantage of
both an external criterion (anchor-based approach) and a meas-
ure of variability (distribution-based approach) to determine the
responder deﬁnition at the individual level, and, therefore, can be
applied as an end-point measure to interpret treatment beneﬁts.
In this article, we tried to determine an a priori responder
deﬁnition of the Chinese-version RSI for patients with LPR in
accordance with the FDA guidance. We ﬁrst tested the reliability
and responsiveness of the RSI in Taiwanese patients with LPR and
assessed whether the target concept of the RSI correlates with an
empirical criterion, that is, 50% or more reduction in the primary
laryngeal symptom [5,17–19]. Furthermore, using this empirical
criterion as the anchor, we attempted to determine a responder
deﬁnition on the basis of the change in the RSI score during the PPI
treatment using the anchor-based method along with the max-
imal Youden index approach for identifying the threshold.Methods
This study was a prospective, open-label therapeutic trial con-
ducted at the Voice & Laryngeal Pathology Laboratory and the
Gastrointestinal Physiology & Motility Laboratory at Taichung
Veterans General Hospital, Taiwan. The protocol was approved
by Taichung Veterans General Hospital’s Institutional Review
Board (no. C06254) on January 29, 2007. All patients signed an
informed consent form before the study.
Patient Selection
Patients (aged 420 years) with chronic laryngeal signs and
symptoms suspected to be reﬂux-related and referred from the
Department of Otolaryngology clinic between January 30, 2007,
and December 31, 2012, were assessed for study eligibility.
Currently, LPR is frequently suspected on the basis of laryngeal
symptoms and signs after excluding common etiologies other than
reﬂux [20]. Because of the nonspeciﬁcity of laryngeal symptoms
and signs, objective measures have been recommended to provide
supportive evidence for diagnosis [4]. The inclusion criteria in the
study were 1) presence of one or more laryngeal symptoms as the
predominant symptom(s), including globus sensation, throat pain,
hoarseness, cough, or throat clearing for three or more consecutive
months before screening and 2) presence of at least one positive
ﬁnding of the following objective tests: a) laryngoscopic signs of
LPR with a Reﬂux Finding Score (RFS) of more than 7 [21], which is
highly recommended for the diagnosis of LPR [4]; b) presence ofreﬂux esophagitis diagnosed by upper gastrointestinal endoscopy;
and c) presence of excessive acid reﬂux demonstrated by 24-hour
ambulatory esophagopharyngeal pH monitoring [1].
Patients were excluded for any of the following conditions: 1)
respiratory or gastrointestinal malignancy; 2) radiation therapy or
surgery for the head, neck, lung, or gastrointestinal tract; 3) trauma
or surgery near the larynx; 4) currently smoking or history of heavy
smoking and substance or alcohol abuse history; 5) infectious
laryngitis in the previous 3 months; 6) exposure to environmental
irritants in the past 3 months; 7) vocal cord papilloma, enlarged
lingual or palatine tonsils, or goiter; 8) excessive voice use; 9)
bronchial asthma; 10) chronic cough attributable to angiotensin-
converting enzyme inhibitor, or known chronic pulmonary or
tracheobronchial etiologies, such as eosinophilic bronchitis, bron-
chiectasis, positive methacholine provocation test result, or
response to inhaled or systemic steroid; 11) pharyngeal (Zenker’s)
diverticulum or esophageal stasis syndrome, such as achalasia;
anxiety or depression with response to at least 1 month of treat-
ment with an anxiolytic or an antidepressant [22]; 12) chronic or
allergic rhinosinusitis, nasal polyposis, or postnasal drip with
response to at least 1 month of medical therapy with antihist-
amine, topical steroid spray, or deﬁned by nasal endoscopy or
computed tomography scan; 13) participation in another investiga-
tional drug study in the previous month; 14) acid suppressive
therapy within 4 weeks before recruitment; 15) need for continuous
therapy with theophylline, iron supplements, warfarin, antifungal
drugs, and digitalis; 16) women were required to be nonpregnant
and nonlactating and to maintain effective contraception if of
child-bearing potential; and 17) had a serious illness that would
interfere with study participation, or refused to participate.
Screening Period
Patients whomet the eligibility criteria were enrolled in a 2- to 4-week
run-in period to screen out ineligible or noncompliant participants
and to conﬁrm that the severity of the primary laryngeal symptom
was unchanged before treatment. We used a self-administered four-
point Likert scale (0 ¼ none, 1 ¼ mild, 2 ¼ moderate, and 3 ¼ severe)
to assess ﬁve laryngeal symptoms (globus sensation, throat pain,
hoarseness, cough, and throat clearing) [19]. Participants identiﬁed
the single most bothersome symptom among the ﬁve symptoms as
the primary laryngeal symptom before treatment. The Likert scale
was used to assess the symptom severity in two assessments 7 to 14
days apart. The severity of the primary laryngeal symptom was
required to be at least moderate (or Z2 points) in both assessments.
Study Design
Participants took an oral esomeprazole 40 mg tablet (Nexium;
AstraZeneca Pharmaceuticals, Södertälje, Sweden) 30 minutes
before breakfast and 30 minutes before dinner because a twice-
daily dose was previously shown to be superior to a regular dose
in a subset of patients [17]. Before esomeprazole treatment, the
RSI instrument was administered at baseline. During the treat-
ment period, patients’ adherence to treatment, adverse events,
and concomitant medication were evaluated and documented by
ﬁlling out the questionnaires with the assistance of the study
nurse at 4-, 8-, and 12-week follow-up visits before an interview
with the investigator (H.-C. Lien). At week 12 after completion of
esomeprazole treatment, each participant ﬁlled out the self-
administered questionnaires including a 10-cm visual analogue
scale to assess the improvement in the primary laryngeal
symptom and the RSI score for outcome measures.
Laryngoscopy and Upper Gastrointestinal Endoscopy
Laryngoscopy was performed using a ﬂexible nasolaryngoscope
(VNL-1171K; Pentax, Tokyo, Japan) to exclude malignancies of the
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at enrollment. The RFS is an eight-item scoring scale for assess-
ing clinical severity, ranging from 0 (no abnormal ﬁnding) to 26
(worst score possible) [21]. The same laryngologist (C.-C. Wang)
performed all the RFS scoring examinations.
The presence of reﬂux esophagitis was evaluated using upper
gastrointestinal endoscopy (GIF XQ-240; Olympus, Tokyo, Japan)
on the basis of Los Angeles classiﬁcation before treatment.
Twenty-Four–Hour Ambulatory Esophagopharyngeal pH
Monitoring
An ambulatory 24-hour pH catheter incorporating three antimony
sensors into a bifurcated probe with a single connector was used
(Sandhill Scientiﬁc, Highlands Ranch, Colo). A detailed description
of the technique has been described previously [23]. Brieﬂy,
manometry was used to position the proximal sensor 1 cm above
the upper esophageal sphincter, the middle sensor at 10 cm distal
to the proximal one, and the distal sensor at 5 cm above the lower
esophageal sphincter. The participants consumed their usual diet
but excluded citrus fruit, acidic beverages, carbonated beverages,
caffeinated beverages, and any antireﬂux medications including
PPIs. An excessive esophagopharyngeal acid reﬂux was deﬁned as the
presence of 1) one or more episode of pharyngeal acid reﬂux [23]
and/or 2) excessive distal esophageal acid reﬂux, that is, 4.6% of
total acid exposure time with pH o 4 at 5 cm above the upper
margin of the lower esophageal sphincter [24].
The RSI Questionnaire
The RSI is a self-administered nine-item symptom questionnaire
and can be completed in less than 1 minute. The scale for each
item ranges from 0 (no problem) to 5 (severe problem), with a
maximum total score of 45 for the assessment of symptom
severity in patients with LPR [8].
Linguistic Translation
Linguistic translation of the RSI from English to Chinese was
performed by two bilingual translators (S.P. Lien and H.-C. Lien)
who independently translated the RSI into Chinese. The two
versions were reconciled in a joint discussion by both translators
to detect errors and to obtain a uniﬁed ﬁnal version. A back
translation was then performed by a native English speaker (A.
Lee) who has lived in Taiwan for 20 years and speaks ﬂuent
Chinese [25]. The back-translated English version was compared
with the original English-version RSI by a committee comprising
a methodologist (W.M. Liang ), a bilingual gastroenterologist (C.S.
Chang), a language professional (S. Brenda), and three translators
(H.-C. Lien, S.P. Lien, and A. Lee). The committee reviewed all the
translations including forward and back translations and reached
a consensus on any discrepancy to produce a preﬁnal version.
Subsequently, a pretest of the preﬁnal version was conducted
using 25 randomly selected patients with LPR with education
levels ranging from elementary school to university. Each partic-
ipant was asked whether he or she had difﬁculty understanding
the Chinese version of the questionnaire. Subsequent modiﬁca-
tions were made according to their suggestions. The ﬁnal version
was approved by the committee with no semantic differences
and no conceptual differences detected compared with the
original English version (see Appendix Fig. 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2015.01.001.
Outcome Measures
Two outcome measures were used to evaluate the esomeprazole
treatment response. One was 50% or more reduction in the
primary laryngeal symptom (globus sensation, throat pain,hoarseness, cough, and throat clearing), which is an empirical
responder criterion to differentiate responders from nonrespond-
ers commonly used in previous LPR clinical trials [5,17–19]. We
used a 10-cm visual analogue scale by asking, “Compared to the
baseline status (before treatment), what is the percentage of
improvement in your primary laryngeal symptom?” (0 cm, no
improvement or deterioration; 10 cm, 100% improvement) at
week 12. Participants were reminded of the single most bother-
some symptom they identiﬁed as the primary laryngeal symptom
among ﬁve laryngeal symptoms before treatment. The other
outcome measure was the change in the total RSI score measured
from baseline to week 12 during the treatment period.
Statistical Analyses
Descriptive statistics were used to summarize demographic data.
To examine overall score distributions, the proportions of
respondents with the lowest (0) and highest possible RSI scores
(45) were calculated for the presence of ﬂoor and ceiling effects.
Validation of the Chinese-version RSI
The Chinese-version RSI was validated by the evaluation of
reliability and responsiveness. The reliability of the RSI was
examined by internal consistency and test-retest reliability. The
internal consistency was assessed by Cronbach α, and the accept-
able overall value of Cronbach α was between 0.7 and 0.9 [26]. The
test-retest reliability was calculated by comparing the RSI scores
between the two visits 7 to 14 days apart before treatment in a
randomly selected subgroup of 43 subjects. The sample size
adequacy for test-retest reliability was examined according to
the guidelines set by Bland and Altman [27], in which the
standard error of the within-subject SD (Sw) is shown to be
dependent on the number of subjects (n) and the number of
observations per study subject (m). Our sample of 43 subjects
with two repetitions (n ¼ 43; m ¼ 2) indicated that we can be
conﬁdent that the estimate of Sw that we obtained was within
22% of its true (population) value [27]. The test-retest reliability
was expressed by intraclass correlation coefﬁcient. Intraclass
correlation coefﬁcient values of more than 0.7 are considered
acceptable [28]. The responsiveness to change during treatment
was evaluated by effect size, which was calculated by dividing
the mean difference between the baseline and week 12 by the SD
at baseline. The effect size was determined to assess the relative
size of change: an effect size of 0.2 was considered to be small, 0.5
to be medium, and 0.8 or greater to be large [29,30].
Conceptual Association between the Anchor and the RSI
The relationship between the targeted concept of the RSI and the
concept measured by the anchor was evaluated by determining
the association between the mean change in RSI scores from
baseline and a 50% or more reduction in the primary laryngeal
symptom at week 12 using t test and effect size.
Anchor-Based Method to Determine responder Deﬁnition on the
RSI
We used the anchored-based method according to the US FDA
recommendation [15]. First, we used an empirical criterion, that
is, 50% or more reduction in the primary laryngeal symptom at
week 12, as the anchor to dichotomize patients into two groups
[16]. A 50% or more reduction in the primary (or global) laryngeal
symptom has been used as an end-point measure in previous
clinical trials [5,17–19]. Second, we plotted the cumulative dis-
tribution of the RSI score change for each group (Fig. 2). We then
deﬁned the sensitivity as cumulative percentage for patients with
50% or more reduction in the primary laryngeal symptom, and
the speciﬁcity as 1  cumulative percentage for patients with less
Table 1 – Demographics variables and clinical baseline characteristics of 96 subjects with suspected
laryngopharyngeal reﬂux.
Variable Total
(N ¼ 96)
Completed* at week 12
(N ¼ 84)
Not completed at week 12
(N ¼ 12)
Age (y), mean  SD 49.5  12.6 49.3  12.6 50.9  13.4
BMI (kg/m2), mean  SD 23.7  3.8 23.6  3.8 23.7  3.6
Sex: male, n (%) 54 (56.3) 50 (59.5) 4 (33.3)
Primary laryngeal symptom, n (%)
Globus sensation 28 (29.2) 25 (29.8) 3 (25.0)
Throat pain 15 (15.6) 14 (16.7) 1 (8.3)
Hoarseness 29 (30.2) 25 (29.8) 4 (33.3)
Cough 15 (15.6) 11 (13.1) 4 (33.3)
Throat clearing 9 (9.4) 9 (10.7) 0 (0.0)
Typical reﬂux syndrome, n (%) 59 (61.5) 52 (61.9) 7 (58.3)
Erosive esophagitis, n (%) 60 (63.2) 55 (66.3) 5 (41.7)
Excessive esophagopharyngeal acid reﬂux, n (%) 49 (51.0) 44 (52.4) 5 (41.7)
Reﬂux Finding Score, median (IQR) 6 (4–7) 6 (4–7) 6 (5–8)
RSI score, median (IQR) 17 (12–22) 17 (12–22) 17.5 (10–26)
BMI, body mass index; IQR, interquartile range; RSI, Reﬂux Symptom Index; typical reﬂux syndrome, heartburn or acid regurgitation.
* Completed: Patients with no missing data at week 12.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 9 6 – 4 0 3 399than 50% reduction in the primary laryngeal symptom. Third, we
plotted the ROC curve on the basis of sensitivity and speciﬁcity
calculated for each point of the RSI score change. Finally, we used
the maximal Youden index from the ROC curve to determine an
optimal cutoff point of the RSI score change that served as the
deﬁnition of responder. The sensitivity and the speciﬁcity were
also calculated in subgroups with different baseline scores, that
is, less than 12, 12 to 27, and 28 or more. A baseline score of less
than 12 was considered to be a low baseline based on the 95%
upper limits of the norm in the previous studies [8,11,12]. A
baseline score of 28 or more was chosen as the high baseline
from the top 10% of the subjects.Results
Flow of Patients
A total of 228 subjects were assessed for eligibility. The intent-to-
treat population consisted of 96 subjects. Twelve subjects
dropped out, so 84 subjects were included in the per-protocol
analysis (see Appendix Fig. 2 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.01.001). Esomeprazole was
generally well tolerated. There was no serious adverse event
requiring emergency care or hospitalization. The most commonly
reported adverse events were abdominal fullness, constipation,
diarrhea, headache, and dyspepsia. There were no differences in
the baseline characteristics between participants and nonparticipantsTable 2 – Floor and ceiling effects, internal consistency,
Chinese-version RSI.
Measure Criterion
Floor effect (%)
Ceiling effect (%)
Internal consistency Cronbach α
Test-retest reliability Intraclass correlation coefﬁcient
Responsiveness Effect size*
Paired t test (P value)
RSI, Reﬂux Symptom Index.
* Effect size, based on Cohen’s deﬁnition d¼ x1x2s ; s¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðn11Þs12 þðn21Þs22
n1 þn2
q
.(Table 1). Among 84 subjects who completed the study, 38
reported 50% or more reduction in the primary laryngeal symp-
tom at week 12. The remaining 46 reported less than 50%
reduction in the primary laryngeal symptom at week 12, includ-
ing 23 subjects with no improvement or deterioration on the
basis of the visual analogue scale (see Appendix Fig. 2 in
Supplemental Materials).Validation of the Chinese-Version RSI
At baseline, there was neither ﬂoor effect nor ceiling effect for
total RSI scores (Table 2). Mean RSI scores changed from 17.5 
7.5 at baseline to 10.8  7.2 at week 12 (P o 0.0001). The Chinese-
version RSI showed a good internal consistency, good test-retest
reliability, and a good responsiveness (Table 2).The Conceptual Association between the Anchor and the RSI
The mean RSI score reduction in 38 subjects with a 50% or more
reduction in the primary laryngeal symptom was signiﬁcantly
greater than that in 46 subjects with a less than 50% reduction in
the primary laryngeal symptom at week 12 (11.0  7.8 vs. 3.1 
8.3, P o 0.0001; effect size 0.99; Fig. 1). Similarly, the mean RSI
score reduction was also greater for individual RSI items in
subjects with a 50% or more reduction in the primary laryngeal
symptom than in those without (see Appendix Fig. 3A in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.jval.2015.01.
001). The phenomenon existed for most items in each subgrouptest-retest reliability, and responsiveness for the
Range Ideal Result
0–100 0.0
0–100 0.0
0–1 40.7 0.74
0–1 40.7 0.79
40.8 0.92
0–1 o0.05 o0.0001
Fig. 1 – Mean changes in RSI scores from baseline between
patients with 50% or more and less than 50% reduction in
the primary laryngeal symptom at week 12. (The “I” bars
represent standard error.) RSI, Reﬂux Symptom Index.
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sample size (see Appendix Fig. 3B-F in Supplemental Materials).The Anchor-Based Method to Determine the Responder
Deﬁnition for the RSI
The cumulative percentage of patients at various cutoff points of
the RSI score reduction showed distinct distributions betweenig. 2 – Illustrative cumulative distribution function shows a dist
eduction of six points from baseline between patients with 50% o
ymptom at week 12. (X-axis, the RSI score change from baselin
umulative percentage for patients with Z50% reduction in the p
ercentage for patients with o50% reduction in the primary larypatients with and without 50% or more reduction in the primary
laryngeal symptom at week 12 (Fig. 2). The ROC curve based on
the sensitivity and speciﬁcity calculated for each point of the RSI
score was plotted, and the area under the ROC curve was 0.77. A
reduction of at least six points in the RSI score from the baseline
was determined to be the deﬁnition of responder on the basis of
the maximal Youden index. The sensitivity was 0.79 and the
speciﬁcity was 0.70 for the diagnosis of a 50% or more reduction
in the primary laryngeal symptom at week 12 (Table 3). The
sensitivity and the speciﬁcity of a six-point reduction in the RSI
score varied at different baseline RSI scores (Table 3), but
remained stable across different subgroups of each primary
laryngeal symptom (see Appendix Table 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2015.01.001).Discussion
In this study, we applied a disease-speciﬁc PRO instrument, the
RSI, in the assessment of patients with LPR to determine an a
priori responder deﬁnition for outcome measure using the
anchor-based method in accordance with the ﬁnal version of
the PRO guidance released by the US FDA in 2009.
There are three major ﬁndings of this study. First, the
Chinese-version RSI was shown to be reliable and responsive to
change during the treatment in Taiwanese patients with LPR.
Second, the empirical criterion, a 50% or more reduction in the
primary laryngeal symptom, was highly correlated with the
change in RSI scores in response to the PPI treatment. Third, a
responder deﬁnition of a reduction of six points or more in the
RSI score at week 12 (possible range 45 to 45) using the anchor-
based method was proposed to measure the treatment beneﬁt.
The FDA guidance emphasizes the importance of taking the
patient’s perspective into account. To capture optimal informa-inct difference in cumulative percentage at the RSI score
r more and less than 50% reduction in the primary laryngeal
e; Y-axis, cumulative percentage of patients; Sensitivity,
rimary laryngeal symptom; Speciﬁcity, 1  cumulative
ngeal symptom). RSI, Reﬂux Symptom Index.
Table 3 – Sensitivity and speciﬁcity of the RSI score reduction of at least six points as responder deﬁnition for
diagnosing an empirical criterion, i.e., Z50% reduction in the primary laryngeal symptom, among all subjects
and among subgroups with different baselines.
Diagnostic performance All Subjects (n ¼ 84) Subgroups with different baselines
o12 (n ¼ 19) 12–27 (n ¼ 56) Z28 (n ¼ 9)
Sensitivity 0.79 (30/38) 0.17 (1/6) 0.90 (26/29) 1.00 (3/3)
Speciﬁcity 0.70 (32/46) 1.00 (13/13) 0.67 (18/27) 0.17 (1/6)
RSI, Reﬂux Symptom Index.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 9 6 – 4 0 3 401tion from the patient’s experience, disease-speciﬁc PRO instru-
ments should be developed on the basis of a review of the
literature and input from physicians and targeted patients.
Currently, only three LPR-speciﬁc symptom questionnaires are
available: the Supraesophageal Reﬂux Questionnaire [31], the
Pharyngeal Reﬂux Symptom Questionnaire [32], and the RSI. Both
the Supraesophageal Reﬂux Questionnaire and the Pharyngeal
Reﬂux Symptom Questionnaire, however, have not been vali-
dated with respect to responsiveness to change during the treat-
ment. In contrast, the RSI instrument was developed and
validated in a sample of pH-test–proven patients with LPR by
Belafsky et al. [8], including good construct validity demonstrated
by patients with a ﬁve-point or better improvement in the RSI
score being 11 times more likely to have a ﬁve-point improve-
ment in the Voice Handicap Index score, and known group
validity demonstrated by a signiﬁcantly higher mean RSI score
(21.2) in patients with LPR before treatment than in asympto-
matic individuals (11.6). In addition, a greater reduction in RSI
scores after the PPI treatment was also found to be associated
with an abnormal pH test result in Chinese patients with
suspected LPR [18].
In the FDA guidance, the anchor-based method using an
empirical criterion is recommended to determine the responder
deﬁnition for the PRO instrument at an individual patient level.
[15]. To be useful, the anchors chosen should have intuitive
meaning, be easier to interpret than the PRO measure itself, and
should correlate well with the target concept of the PRO instru-
ment. In this study, we chose a 50% or more reduction in the
primary laryngeal symptom as the anchor because it was the
primary or the most bothersome laryngeal symptom identiﬁed by
the patient and has been used as an end-point measure in previous
clinical trials [5,17–19]. In addition, previous focus group discus-
sions have revealed that LPR-related symptoms such as voice
problems, chronic cough, throat clearing, and swallowing difﬁcul-
ties are the key concerns of patients with LPR and negatively affect
health-related quality of life [33]. Our ﬁnding of a high correlation
between the mean RSI score reduction from baseline and a 50% or
more reduction in the primary laryngeal symptom at treatment
end may therefore justify the application of the anchor chosen to
determine the responder deﬁnition for the RSI instrument. Alter-
natively, a laryngoscopic signs scoring system, such as the RFS [21],
or a 50% or more reduction in the global laryngeal symptom [5]
may be considered as possible anchor candidates. The former,
however, may require a longer duration to observe any change [34],
and may not correlate well with symptoms [35], whereas the latter
averages a complex of changes in symptoms over a long period of
time and is subject to recall bias.
Recently, Vakil et al. [36] reviewed current PRO instruments in
gastroesophageal reﬂux disease and found that only ﬁve have
been used as end points in clinical trials. Among them, either no
responder was deﬁned or responder was deﬁned as freedom from
symptoms. Alternatively, the Reﬂux Questionnaire-GI subscale
uses a score below 1.73 derived from the 95th percentile of healthy
controls to deﬁne symptomatic response [37]. The use of suchdistribution-based methods as the sole basis for determining a
responder deﬁnition, however, is considered supportive but not
appropriate in the FDA guidance [15]. Traditionally, the disadvant-
age of the distribution-based approach is that it does not provide
information about the clinical importance, whereas the disadvant-
age of the anchor-based method is its inability to take into account
the variability of the instrument and/or the sample. In this study,
we combined the anchor-based and distribution-based methods to
take advantage of both an external criterion and a measure of
variability [16]. With the anchor-based method, the patients can be
dichotomized into with and without marked improvement. With
these two sample distributions, the optimal cutoff value of the
score change in the PRO instrument can be determined using an
ROC curve with the maximal Youden index. Using these
approaches, we found that the cutoff value was a reduction of
six points or more in the RSI score from baseline, which had a
sensitivity of 79% and a speciﬁcity of 70% for the prediction of the
anchor (Fig. 2). In addition, the value of a six-point change remains
quite stable across the ﬁve primary laryngeal symptoms (see
Appendix Table 1 in Supplemental Materials), suggesting its
suitability for use as a responder deﬁnition in future clinical trials.
The responder deﬁnition of the RSI instrument in our study
may be advantageous in both clinical practice and clinical trials,
because it enables the interpretation of the treatment beneﬁt at
the patient level, thereby facilitating the patient-doctor commu-
nication with respect to the treatment efﬁcacy. In addition, it
assesses the current state in a complex of LPR symptoms with no
or little recall bias, and therefore can appropriately reﬂect the
health status of individuals in real time. Furthermore, this
method is also likely to be superior to the use of the conventional
minimally important difference [14], which was derived from
point estimates of intrapatient mean group change, possibly
masking individual important change, and therefore was not
included in the revised 2009 FDA guidance.
There may, however, be some limitations. First, the responder
deﬁnition of the RSI based on a score reduction of six points or
more may not be invariant across various baseline values using
our approach. Patients with a low baseline RSI score (o12) have a
low sensitivity, whereas patients with a high baseline RSI score
(Z28) have a low speciﬁcity in the prediction of the anchor
(Table 3). Not surprisingly, patients with a baseline RSI score of
less than 12, which is within the range of normal controls in
previous studies [8,11,12], may have either fewer or less severe
symptoms, and thus are less likely to have a reduction of six
points despite adequate or complete relief of the primary lar-
yngeal symptom. In contrast, a high baseline RSI score of 28 or a
larger arbitrarily chosen value on the basis of the top 10% of our
study subjects may indicate an outlier value. Such patients may
have either more symptom items or more severe symptom.
Because of the phenomenon of “regression to the mean,” they
are likely to have a reduction of six points or more despite
inadequate relief of the primary laryngeal symptom. This may
be an inherent limitation of using the PRO instrument for the
determination of a responder deﬁnition. In such patients with
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 9 6 – 4 0 3402high baseline RSI score, a different cutoff point may be required
to deﬁne another responder deﬁnition [16]. In addition, the value
of a high baseline RSI score may vary from study to study. Future
large-scale studies may need to clarify these issues. Second, the
precision of a six-point estimate may be limited because data
were obtained from a relatively small sample size in a single
referral center. This limitation, however, may be attenuated in
part by applying a reliable and responsive PRO instrument in a
cohort receiving medications with a long follow-up period.
Nevertheless, future research is warranted to conﬁrm our ﬁnd-
ings. Third, the RSI lacks content concerning frequency and
duration of symptoms [32] and the focus group discussion was
not mentioned in the development study [8]. Despite its imper-
fections, however, it was shown to be superior to other validated
LPR-speciﬁc symptom questionnaires in terms of ease in practice,
widespread use, and containing most relevant symptoms.
Finally, the RSI instrument consisted of eight throat-symptom
items and one esophageal-symptom item, and should only be
used in patients with major complaint of reﬂux-related throat
symptoms if a responder deﬁnition is to be used as the end point
of PRO measures.Conclusions
We found that a reduction of six points or more in the RSI score
from baseline was sufﬁciently sensitive and speciﬁc for use as the
responder deﬁnition to interpret the treatment beneﬁt in patients
with LPR. This responder deﬁnition meets the US FDA guidance
for industry to evaluate PROs in medical product development to
support labeling claims, and may be used as the end-point
measure in clinical practice and clinical trials. A reduction of
six points or more in the RSI score, however, is a preliminary
estimate, and additional studies across other language versions
are required.Acknowledgments
We thank Dr. Belafsky for his generosity to agree to do the
translation of the Reﬂux Symptom Index into Chinese language,
Dr. El-Wui Loh from Kaohsiung Municipal Kai-Syuan Psychiatric
Hospital of Taiwan for his valuable comments, and Ms Kareen
Chong for her secretarial work. Parts of information given in this
article have been used in a poster presentation at the Third
Biennial Conference of the Asian Neurogastroenterology and
Motility Association, Penang, Malaysia, March 1, 2013.
Source of ﬁnancial support: Taiwan’s Ministry of Science and
Technology supported this study (grant no. NSC102-2314-B-075A-
004-MY2).Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at http://dx.doi.org/10.1016/j.
jval.2015.01.001 or, if a hard copy of article, at www.valueinhealth
journal.com/issues (select volume, issue, and article).
R E F E R N C E S[1] Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reﬂux:
position statement of the Committee on Speech, Voice, and Swallowing
Disorders of the American Academy of Otolaryngology - Head and Neck
Surgery. Otolaryngol Head Neck Surg 2002;127:32–5.[2] Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal deﬁnition and
classiﬁcation of gastroesophageal reﬂux disease: a global evidence-
based consensus. Am J Gastroenterol 2006;101:1900–20.
[3] Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological
Association Medical Position Statement on the management of
gastroesophageal reﬂux disease. Gastroenterology 2008;135:
1383–91.
[4] Ford CN. Evaluation and management of laryngopharyngeal reﬂux.
JAMA 2005;294:1534–40.
[5] Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor
therapy for suspected GERD-related chronic laryngitis: a meta-
analysis of randomized controlled trials. Am J Gastroenterol
2006;101:2646–54.
[6] Reichel O, Dressel H, Wiederänders K, Double-blind Issing WJ. placebo-
controlled trial with esomeprazole for symptoms and signs associated
with laryngopharyngeal reﬂux. Otolaryngol Head Neck Surg
2008;139:414–20.
[7] Lam PK, Ng ML, Cheung TK, et al. Rabeprazole is effective in treating
laryngopharyngeal reﬂux in a randomized placebo-controlled trial. Clin
Gastroenterol Hepatol 2010;8:770–6.
[8] Belafsky PC, Postma GN, Koufman JA. Validity and reliability of reﬂux
symptom index (RSI). J Voice 2002;16:274–7.
[9] Schindler A, Mozzanica F, Ginocchio D, et al. Reliability and
clinical validity of the Italian Reﬂux Symptom Index. J Voice
2010;24:354–8.
[10] Printza A, Kyrgidis A, Oikonomidou E, Triaridis S. Assessing
laryngopharyngeal reﬂux symptoms with the Reﬂux Symptoms Index:
validation and prevalence in Greek population. Otolaryngol Head Neck
Surg 2011;145:974–80.
[11] Farahat M, Malki KH, Mesallam TA. Development of the Arabic version
of Reﬂux Symptom Index. J Voice 2012;26(814):e15–9.
[12] Cohen JT, Gil Z, Fliss DM. The reﬂux symptom index–a clinical tool for
the diagnosis of laryngopharyngeal reﬂux. Harefuah 2005;144:826–9:
(912).
[13] Wright JG. The minimal important difference: who’s to say what is
important? J Clin Epidemiol 1996;49:1221–2.
[14] Hays RD, Farivar SS, Liu H. Approaches and recommendations for
estimating minimally important differences for health-related quality
of life measures. COPD 2005;2:63–7.
[15] U.S. Department of Health and Human Services, Food and Drug
Administration. Guidance for industry 2009; Patient-reported outcome
measures: use in medical product development to support labeling
claims. Available from: http://www.fda.gov/downloads/Drugs/
Guidances/UCM193282.pdf. [Accessed March 23, 2014].
[16] de Vet HC, Ostelo RW, Terwee CB, et al. Minimally important change
determined by a visual method integrating an anchor-based and a
distribution-based approach. Qual Life Res 2007;16:131–42.
[17] Park W, Hicks DM, Khandwala F, et al. Laryngopharyngeal reﬂux:
prospective cohort study evaluating optimal dose of proton-pump
inhibitor therapy and pretherapy predictors of response. Laryngoscope
2005;115:1230–8.
[18] Lien HC, Wang CC, Liang WM, et al. Composite pH predicts
esomeprazole response in laryngopharyngeal reﬂux without typical
reﬂux syndrome. Laryngoscope 2013;123:1483–9.
[19] Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior
laryngitis with esomeprazole. Laryngoscope 2006;116:254–60.
[20] Ahmed TF, Khandwala F, Abelson TI, et al. Chronic laryngitis
associated with gastroesophageal reﬂux: prospective assessment of
differences in practice patterns between gastroenterologists and ENT
physicians. Am J Gastroenterol 2006;101:470–8.
[21] Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the
reﬂux ﬁnding score (RFS). Laryngoscope 2001;111:1313–7.
[22] Oyer SL, Anderson LC, Halum SL. Inﬂuence of anxiety and depression
on the predictive value of the reﬂux symptom index. Ann Otol Rhinol
Laryngol 2009;118:687–92.
[23] Lien HC, Wang CC, Hsu JY, et al. Classical reﬂux symptoms, hiatus
hernia and overweight independently predict pharyngeal acid
exposure in patients with suspected reﬂux laryngitis. Aliment
Pharmacol Ther 2011;33:89–98.
[24] Hu WH, Wong NY, Lai KC, et al. Normal 24-hour ambulatory proximal
and distal gastroesophageal reﬂux parameters in Chinese. Hong Kong
Med J 2002;8:168–71.
[25] Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of
health-related quality of life measures: literature review and proposed
guidelines. J Clin Epidemiol 1993;46:1417–32.
[26] DeVellis RF. Scale Development. (2nd ed.). Thousand Oaks, Calif: Sage,
2003.
[27] Bland JM, Altman DG. Statistics notes: measurement error. BMJ
1996;313:744.
[28] Nunnally JC, Bernstein IH. Psychometric Theory. New York: McGraw-
Hill, 1994.
[29] Cohen J. Statistical Power Analysis for the Behavioural Sciences. New
York: Academic Press, 1977.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 9 6 – 4 0 3 403[30] Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes
in health status. Med Care 1989;27(3, Suppl.):S178–89.
[31] Dauer E, Thompson D, Zinsmeister AR, et al. Supraesophageal reﬂux:
validation of a symptom questionnaire. Otolaryngol Head Neck Surg
2006;134:73–80.
[32] Andersson O, Rydén A, Ruth M, et al. Development and validation
of a laryngopharyngeal reﬂux questionnaire, the Pharyngeal
Reﬂux Symptom Questionnaire. Scand J Gastroenterol 2010;45:
147–59.
[33] Lenderking WR, Hillson E, Crawley JA, et al. The clinical characteristics
and impact of laryngopharyngeal reﬂux disease on health-related
quality of life. Value Health 2003;6:560–5.[34] Belafsky PC, Postma GN, Koufman JA. Laryngopharyngeal reﬂux
symptoms improve before changes in physical ﬁndings. Laryngoscope
2001;111:979–81.
[35] Belafsky PC, Postma GN, Amin MR, Koufman JA. Symptoms and
ﬁndings of laryngopharyngeal reﬂux. Ear Nose Throat J 2002;81(9,
Suppl. 2):10–3.
[36] Vakil NB, Halling K, Becher A, Rydén A. Systematic review of patient-
reported outcome instruments for gastroesophageal reﬂux disease
symptoms. Eur J Gastroenterol Hepatol 2013;25:2–14.
[37] Stanghellini V, Armstrong D, Mönnikes H, et al. Determination of
ReQuest-based symptom thresholds to deﬁne symptom relief in GERD
clinical studies. Digestion 2005;71:145–51.
